Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
CytoDyn to hold a conference call » 15:25
08/12/20
08/12
15:25
08/12/20
15:25
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Pourhassan, Chief Medical Officer Kelly and Senior Science Advisor Lalezari provide an overview of the results from the Company's recently completed Phase 2 CD10 Trial for COVID-19 patients with mild-to-moderate symptoms, along with an update on its Phase 3 trial for COVID-19 patients with severe-to-critical indications and the regulatory path going forward on a conference call to be held on August 12 at 4 pm. Webcast Link

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Conference/Events
CytoDyn to hold a conference call » 09:51
08/12/20
08/12
09:51
08/12/20
09:51
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Pourhassan, Chief Medical Officer Kelly and Senior Science Advisor Lalezari provide an overview of the results from the Company's recently completed Phase 2 CD10 Trial for COVID-19 patients with mild-to-moderate symptoms, along with an update on its Phase 3 trial for COVID-19 patients with severe-to-critical indications and the regulatory path going forward on a conference call to be held on August 12 at 4 pm. Webcast Link

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Tuesday
Hot Stocks
CytoDyn reports topline results from Phase 2 trial in COVID-19 patients » 09:21
08/11/20
08/11
09:21
08/11/20
09:21
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

CytoDyn announced the…

CytoDyn announced the Top-line results from its recently completed, randomized, double-blind, Phase 2 trial for COVID-19 patients with mild-to-moderate symptoms. CytoDyn will submit its Top-line Report for this trial to the U.S. Food and Drug Administration for review later this week. The Top-line Report revealed the following information: Clinical improvement assessed by change in total clinical symptom score: In patients with Total Clinical Symptom Score of greater than or equal to 4 at baseline: At Day 3, more subjects treated with leronlimab reported improvement in total clinical symptom score compared to the placebo group. The subgroup analysis indicates that among patients with more symptoms at baseline, those who received leronlimab had a greater treatment effect than patients who received the placebo. The National Early Warning Score is an objective scale developed by the Royal College of Physicians to identify patients at risk for rapid clinical deterioration requiring critical care intervention. NEWS2, is being used as an endpoint in several other COVID-19 clinical trials, including CytoDyn's severe-to-critical COVID-19 Phase 3 trial. It measures clinical parameters including respiratory rate, oxygen saturation, supplemental oxygen, temperature, systolic blood pressure, heart rate, and level of consciousness. In all treated patients, at the End of Treatment, patients in the leronlimab group were more than twice as likely to experience a beneficial improvement in scores compared to patients in the placebo group. Similar, statistically significant, results were observed at Day 3 and Day 14 in the analysis of per protocol population. The incidence, frequency, and severity of adverse events and serious adverse events were lower in the leronlimab group compared to the placebo group. Patients treated with placebo were more than twice as likely to experience SAEs or AEs compared to patients treated with leronlimab.

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Over a week ago
Hot Stocks
CytoDyn gets positive DSMC recommendation for Leronlimab Phase 3 COVID-19 trial » 16:36
08/04/20
08/04
16:36
08/04/20
16:36
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

CytoDyn announced an…

CytoDyn announced an independent Data Safety Monitoring Committee, or DSMC, completed its first safety review of the ongoing Phase 3 clinical trial in patients with severe and critical COVID-19 and reported it saw no cause to modify the study. The DSMC reviewed compiled safety data from 149 subjects enrolled in the CD12 trial. The DSMC did not raise any concerns regarding safety and recommended that the trial continue. The Phase 3 study currently has 169 enrolled patients and the company will conduct a full interim analysis once 195 patients are enrolled, as provided in the trial's protocol.

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Conference/Events
CytoDyn to host conference call » 15:55
07/30/20
07/30
15:55
07/30/20
15:55
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Pourhassan and Chief Medical Officer Kelly hold a conference call to provide updates on the Company's two trials for COVID-19 patients on July 30 at 4 pm. Webcast Link

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Conference/Events
CytoDyn to host conference call » 04:55
07/30/20
07/30
04:55
07/30/20
04:55
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Pourhassan and Chief Medical Officer Kelly hold a conference call to provide updates on the Company's two trials for COVID-19 patients on July 30 at 4 pm. Webcast Link

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Conference/Events
CytoDyn to host conference call » 12:40
07/29/20
07/29
12:40
07/29/20
12:40
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Pourhassan and Chief Medical Officer Kelly hold a conference call to provide updates on the Company's two trials for COVID-19 patients on July 30 at 4 pm. Webcast Link

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Periodicals
CytoDyn's promised Yang study a letter, doesn't deal with leronlimab, STAT says » 13:51
07/21/20
07/21
13:51
07/21/20
13:51
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

Adam Feuerstein of STAT…

Adam Feuerstein of STAT News tweeted: "For my $CYDY fans: Remember the promise made by Nader about Dr. Otto Yang publishing his leronlimab data in NEJM? Well, there is no Yang study; it's a letter, co-authored by other UCLA docs; and does not deal with leronlimab." The biotech reporter attached a link to his tweet that points to a letter to the editors of the NEJM regarding "Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19" Reference Link

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Hot Stocks
CytoDyn reports safety data from Phase 2 trial of leronlimab » 06:08
07/21/20
07/21
06:08
07/21/20
06:08
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

CytoDyn announced the…

CytoDyn announced the results of the patient safety data from the company's over-enrolled COVID-19 Phase 2 trial for mild-to-moderate indications. A total of 84 patients were treated across 8 study sites in the randomized, double-blind, placebo-controlled Phase 2 study. Fifty-six patients were assigned to the leronlimab arm compared to 28 patients in the randomized placebo arm with a 2:1 active drug to placebo ratio. This trial was designed to evaluate the safety and efficacy of leronlimab and the results of efficacy portion of the data is anticipated to be released as soon as the statistical analyses of all primary and secondary endpoints are completed. In this Phase 2 study, 34% (19 of 56 patients) treated with leronlimab compared to 50% (14 of 28 patients) treated with placebo reported at least one adverse event. A total of 19 serious adverse events were reported during the study. Eleven SAEs were reported in 6 patients receiving placebo compared to eight SAEs in 5 patients receiving leronlimab. None of the SAEs in the leronlimab arm were deemed related to study drug administration by the investigators. Of the 84 patients treated, one patient died 33 days after enrollment due to an event unrelated to leronlimab. Scott Kelly, M.D., CytoDyn's Chief Medical Officer, commented, "We are very pleased with the safety results in the double-blinded, placebo-controlled study of the mild-to-moderate COVID-19 population. When considering treatment options in the COVID-19 population, it is paramount in treating this complex disease to provide patients with therapeutic options that minimize SAEs. We believe the significant reduction in SAEs in the leronlimab group ultimately translates into improved patient clinical outcomes. Prior drugs in clinical trials for the treatment of COVID-19 have resulted in an increase in SAEs in the drug treated arm versus placebo. We are extremely proud of these results."

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Conference/Events
CytoDyn CEO Dr. Pourhassan to Appear on DrBeen Webcast » 20:50
07/18/20
07/18
20:50
07/18/20
20:50
CYDY

CytoDyn

$0.00 /

+ (+0.00%)

President & CEO…

President & CEO Pourhassan, PhD will be interviewed by Mobeen Syden, MD M.S. on the DrBeen Webcast on July 18 at 9 pm. Webcast Link

ShowHide Related Items >><<
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
04/28/20 H.C. Wainwright
CytoDyn price target raised to $4 from $3 at H.C. Wainwright
04/03/20 H.C. Wainwright
CytoDyn price target raised to $3 from $1.50 at H.C. Wainwright
12/19/19 H.C. Wainwright
CytoDyn price target raised to $1.50 from $1.00 at H.C. Wainwright
CYDY CytoDyn
$0.00 /

+ (+0.00%)

CYDY CytoDyn
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.